News
ABBV
216.49
-2.14%
-4.74
AbbVie (ABBV) Stock After DCF Upside And Elevated P/E Multiple
Simply Wall St · 2h ago
AbbVie would gain an experimental eczema drug by buying biotech: report
MarketWatch · 8h ago
AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics
Seeking Alpha · 13h ago
M&A News: AbbVie Lining up $11B Deal for Eczema Drug Maker Apogee Therapeutics
TipRanks · 1d ago
AbbVie: Immunology Cash Flow Funds Oncology Expansion
Seeking Alpha · 1d ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 1d ago
AbbVie (ABBV) Wins FDA Nod For SKINVIVE While CLL Trial Data Strengthens Pipeline
Simply Wall St · 1d ago
TherapeuticsMD Inc. Stock Slides 14.1%, Underperforms Market
Dow Jones · 2d ago
AbbVie declares $1.73 dividend
Seeking Alpha · 2d ago
Press Release: AbbVie Declares Quarterly Dividend
Dow Jones · 2d ago
AbbVie Declares Quarterly Dividend
PR Newswire · 2d ago
IWF, COST, ABBV, ORCL: Large Outflows Detected at ETF
NASDAQ · 2d ago
Abivax: Safety Signals Loom Ahead Of The NDA Submission
Seeking Alpha · 2d ago
AbbVie’s New Phase 3 Colorectal Cancer Trial Puts ABBV-400 in the Late-Stage Spotlight
TipRanks · 3d ago
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
NASDAQ · 3d ago
AbbVie: Maintaining My Strong Buy Rating After Label Expansion
Seeking Alpha · 4d ago
AbbVie gains approval of Juvederm injectable for neck wrinkles
Seeking Alpha · 4d ago
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
NASDAQ · 4d ago
Allergan Aesthetics Wins FDA Approval For SKINVIVE To Improve Neck Appearance
NASDAQ · 4d ago
FDA Approves AbbVie's SKINVIVE For Neck Line Reduction
NASDAQ · 4d ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.